CCNE1 and gastric adenocarcinoma: In contrast, patients with CCNE1-amplified gastric adenocarcinoma exhibited a trend toward improved survival after receiving immunotherapy with a PD1 or PD-L1 inhibitor (HR = 0.541, 95% CI: 0.239–1.226, P = 0.134; Fig. 4F).